# Phase I CTX310 results show one-year lipid reductions

_Friday, September 4, 2026 at 1:20 PM EDT · Science · Latest · Tier 2 — Notable_

![Phase I CTX310 results show one-year lipid reductions — Primary](https://scx2.b-cdn.net/gfx/news/2026/cleveland-clinic-first.jpg)

Cleveland Clinic reported 12-month Phase I results for CTX310, a one-time CRISPR-Cas9 infusion for medication-resistant lipid disorders. Among 15 participants, those given the highest dose had LDL cholesterol 52.5% below baseline and triglycerides 47.8% below baseline after a year, the report said. The treatment is designed to switch off ANGPTL3 in the liver. No treatment-related serious adverse events were reported during follow-up. Longer-term safety follow-up is planned for 15 years, and the therapy remains experimental.

## Sources

- [Medical Xpress](https://medicalxpress.com/news/2026-09-crispr-gene-therapy-safely-lowers.html)

---
Canonical: https://techandbusiness.org/newswire/XO4DgqmWMlokgh39KS2cwt
Retrieved: 2026-09-04T20:41:54.813Z
Publisher: Tech & Business (techandbusiness.org)